US 11,732,044 B2
Anti-LAG-3 antibody and use thereof
Xiaoniu Miao, Jiangsu (CN); Huajing Hu, Jiangsu (CN); Andy Tsun, Jiangsu (CN); Junjian Liu, Jiangsu (CN); and Xiaolin Liu, Jiangsu (CN)
Assigned to INNOVENT BIOLOGICS (SUZHOU) CO., LTD., Jiangsu (CN)
Appl. No. 16/759,722
Filed by INNOVENT BIOLOGICS (SUZHOU) CO., LTD., Jiangsu (CN)
PCT Filed Dec. 27, 2018, PCT No. PCT/CN2018/124315
§ 371(c)(1), (2) Date Apr. 27, 2020,
PCT Pub. No. WO2019/129137, PCT Pub. Date Jul. 4, 2019.
Claims priority of application No. 201711449486.7 (CN), filed on Dec. 27, 2017; and application No. 201811561512.X (CN), filed on Dec. 19, 2018.
Prior Publication US 2021/0371529 A1, Dec. 2, 2021
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 39/395 (2006.01); C07K 16/28 (2006.01); A61K 47/68 (2017.01); A61K 45/06 (2006.01); C12N 15/85 (2006.01); A61K 39/00 (2006.01)
CPC C07K 16/2818 (2013.01) [A61K 45/06 (2013.01); A61K 47/6851 (2017.08); C07K 16/2803 (2013.01); C07K 16/2878 (2013.01); C12N 15/85 (2013.01); A61K 2039/507 (2013.01); C07K 2317/24 (2013.01); C07K 2317/31 (2013.01); C07K 2317/52 (2013.01); C07K 2317/565 (2013.01); C07K 2317/732 (2013.01); C07K 2317/76 (2013.01); C07K 2317/92 (2013.01)] 21 Claims
OG exemplary drawing
 
1. An antibody or an antigen-binding fragment thereof that binds to LAG-3, the antibody comprising a heavy chain variable region and a light chain variable region, wherein the heavy chain variable region comprises HCDR1, HCDR2, HCDR3, and the light chain variable region comprises LCDR1, LCDR2 and LCDR3, wherein the HCDR1, HCDR2, HCDR3, LCDR1, LCDR2 and LCDR3 comprises or consists of the amino acid sequences respectively represented by
(i) SEQ ID NO: 4, 7, 9, 11, 13 and 16;
(ii) SEQ ID NO: 1, 5, 8, 11, 13 and 14;
(iii) SEQ ID NO: 2, 6, 9, 11, 13 and 15; or
(iv) SEQ ID NO: 3, 7, 10, 12, 13, and 16.